Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
de Wit R, Vaughn DJ, Fradet Y, Fong L, Climent MA, Necchi A, Petrylak DP, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Bajorin DF, Choueiri TK, Xu J, Imai K, Homet Moreno B, Bellmunt J, Lee JL. de Wit R, et al. Among authors: gerritsen wr. Eur Urol. 2024 Aug 21:S0302-2838(24)02498-9. doi: 10.1016/j.eururo.2024.07.015. Online ahead of print. Eur Urol. 2024. PMID: 39174409 Free article.
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer SH, van Wilpe S, Geerlings MJ, von Rhein D, Smilde TJ, Kloots ISH, Westdorp H, Coskuntürk M, Oving IM, van Ipenburg JA, van der Heijden AG, Hofste T, Weiss MM, Schalken JA, Gerritsen WR, Ligtenberg MJL, Mehra N. Tolmeijer SH, et al. Among authors: gerritsen wr. Eur Urol Oncol. 2024 Apr;7(2):282-291. doi: 10.1016/j.euo.2023.08.009. Epub 2023 Sep 4. Eur Urol Oncol. 2024. PMID: 37673768 Free article.
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES. Graff JN, et al. Among authors: gerritsen wr. Prostate Cancer Prostatic Dis. 2024 Aug 12. doi: 10.1038/s41391-024-00865-5. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39134652
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.
van Wilpe S, Kloots ISH, Slootbeek PHJ, den Brok M, Westdorp H, Franken MD, Coskunturk M, Osinga T, Bloemendal H, Adema G, Smeenk RJ, Nagarajah J, van Ipenburg J, Kroeze LI, Ligtenberg MJL, Schalken J, Gerritsen WR, Mehra N. van Wilpe S, et al. Among authors: gerritsen wr. Ann Oncol. 2024 Dec;35(12):1126-1137. doi: 10.1016/j.annonc.2024.09.004. Epub 2024 Sep 16. Ann Oncol. 2024. PMID: 39293514 Free article. Clinical Trial.
An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer.
Privé BM, Muselaers CHJ, van Oort IM, Janssen MJR, Peters SMB, van Gemert WAM, Uijen MJM, Schilham MMG, Sedelaar JPM, Westdorp H, Mehra N, Gotthardt M, Barentsz JO, Gerritsen WR, Witjes JA, Nagarajah J. Privé BM, et al. Among authors: gerritsen wr. Front Nucl Med. 2022 May 3;2:863101. doi: 10.3389/fnume.2022.863101. eCollection 2022. Front Nucl Med. 2022. PMID: 39354959 Free PMC article.
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bosch D, van der Velden KJM, Oving IM, Wyndaele DNJ, Weijs LE, van Schelven WD, Oyen WJG, Te Beek ET, van de Luijtgaarden ACM, Somford DM, Nagarajah J, Hermsen R, Mehra N, Gerritsen WR, van der Doelen MJ, van Oort IM. Bosch D, et al. Among authors: gerritsen wr. J Nucl Med. 2024 Apr 1;65(4):541-547. doi: 10.2967/jnumed.123.266654. J Nucl Med. 2024. PMID: 38423781
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Bloemendal M, Bol KF, Boudewijns S, Gorris MAJ, de Wilt JHW, Croockewit SAJ, van Rossum MM, de Goede AL, Petry K, Koornstra RHT, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Bloemendal M, et al. Among authors: gerritsen wr. Oncoimmunology. 2021 Dec 30;11(1):2015113. doi: 10.1080/2162402X.2021.2015113. eCollection 2022. Oncoimmunology. 2021. PMID: 36524210 Free PMC article. Clinical Trial.
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF, Schreibelt G, Bloemendal M, van Willigen WW, Hins-de Bree S, de Goede AL, de Boer AJ, Bos KJH, Duiveman-de Boer T, Olde Nordkamp MAM, van Oorschot TGM, Popelier CJ, Pots JM, Scharenborg NM, van de Rakt MWMM, de Ruiter V, van Meeteren WS, van Rossum MM, Croockewit SJ, Koeneman BJ, Creemers JHA, Wortel IMN, Angerer C, Brüning M, Petry K, Dzionek A, van der Veldt AA, van Grünhagen DJ, Werner JEM, Bonenkamp JJ, Haanen JBAG, Boers-Sonderen MJ, Koornstra RHT, Boomsma MF, Aarntzen EHJ, Gotthardt M, Nagarajah J, de Witte TJM, Figdor CG, de Wilt JHW, Textor J, de Groot JWB, Gerritsen WR, de Vries IJM. Bol KF, et al. Among authors: gerritsen wr. Nat Commun. 2024 Feb 23;15(1):1632. doi: 10.1038/s41467-024-45358-0. Nat Commun. 2024. PMID: 38395969 Free PMC article. Clinical Trial.
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.
van den Bergh GPA, Kuppen MCP, Westgeest HM, Mehra N, Gerritsen WR, Aben KKH, van Oort IM, van Moorselaar RJA, Somford DM, van den Eertwegh AJM, Bergman AM, van den Bergh ACM, Uyl-de Groot CA. van den Bergh GPA, et al. Among authors: gerritsen wr. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):162-169. doi: 10.1038/s41391-022-00605-7. Epub 2022 Oct 12. Prostate Cancer Prostatic Dis. 2023. PMID: 36224377 Clinical Trial.
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
van der Doelen MJ, Oving IM, Wyndaele DNJ, van Basten JP, Terheggen F, van de Luijtgaarden ACM, Oyen WJG, van Schelven WD, van den Berkmortel F, Mehra N, Janssen MJR, Prins JB, Gerritsen WR, Custers JAE, van Oort IM. van der Doelen MJ, et al. Among authors: gerritsen wr. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):142-150. doi: 10.1038/s41391-022-00569-8. Epub 2022 Jul 8. Prostate Cancer Prostatic Dis. 2023. PMID: 35804188 Free PMC article.
192 results